Novartis: FDA approves Cosentyx
(CercleFinance.com) - Novartis announces that Cosentyx has received FDA approval for a new indication in the treatment of active non-radiographic axial spondyloarthritis.
FDA approval for Cosentyx is based on the PREVENT Phase III trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the spectrum of axial spondyloarthritis (axSpA) disease.
In the US, an estimated 2.7 million people have axial spondylarthritis (axSpA).
The results of the PREVENT trial show that there was a significant reduction in disease activity in patients treated with Cosentyx compared to placebo, said Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics at Oregon Health & Science University, and investigator in the PREVENT trial.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
FDA approval for Cosentyx is based on the PREVENT Phase III trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the spectrum of axial spondyloarthritis (axSpA) disease.
In the US, an estimated 2.7 million people have axial spondylarthritis (axSpA).
The results of the PREVENT trial show that there was a significant reduction in disease activity in patients treated with Cosentyx compared to placebo, said Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics at Oregon Health & Science University, and investigator in the PREVENT trial.
Copyright (c) 2020 CercleFinance.com. All rights reserved.